Safety and Effectiveness of Sirolimus Eluting Stent for Left Main Coronary Artery Stenosis

Seung-Jung Park, MD, PhD, FACC

Asan Medical Center, Seoul, Korea



### Background

- Several trials have reported the safety and feasibility of stenting for left main coronary artery (LMCA) stenosis with favorable procedural and long-term outcomes in the era of bare metal stents(BMS).
- However, there was very limited data in the era of drug eluting stents

### Background

 And, the restenosis remains the major problem limiting the late outcome after PCI in the era of BMS.

#### Unprotected Left Main Stenting Restenosis Rate & TLR at overall



#### 6 month Angiographic Restenosis According to different strategy



# Objective

 The present study was performed to evaluate the safety and efficacy of the sirolimus eluting stent (Cypher<sup>TM</sup> stent; Cordis) for unprotected LMCA narrowing in selected patients.

### **Inclusion Criteria**

 The patients who had unprotected LMCA stenosis (diameter stenosis ≥ 50%) with normal LV function and refused surgery were included.

### **Exclusion Criteria**

- Contraindication to antiplatelet agents
- Bailout stenting
- Primary angioplasty in acute myocardial infarction
- Left ventricular dysfunction (ejection fraction <40%)</li>
- An inability to follow the protocol

# **Follow Up**

- Follow-up information was obtained by regular outpatient evaluation and by telephone contact.
- Angiographic follow-up is being routinely performed at six months or earlier if a patient shows symptoms of recurrence.

### **Subjects**

#### February 19 ~ October 4

Total 74 patients with normal LV function who underwent elective senting for unprotected LMCA stenosis were included. Unprotected Left Main Stenting Antiplatelet Regimens

**Triple combination** 

Aspirin indefinitely Cilostazol 100 mg BID for 1 month Clopidogrel 75 mg QD for 6 month

\* Use of Reopro : 3 cases (7 %) at operator's discretion

#### AMC experience

### **Baseline Demographics**

Age,yrs Men Diabetes Hypertension Current smoker Hypercholesterolemia LV ejection fraction (%)

n = 74 $58 \pm 12$  (33-88) 54 (73 %) 20 (27 %) 23 (31 %) 18 (24 %) 4(6%) $58 \pm 9$ 

**Unprotected Left Main Stenting** 

# **Lesion Location** Total 74 patients

Proximal involvement \*

17 (23 %)

Distal involvement

57 (77 %)

\* Include 2 case confined to LMCA shaft

### **Baseline Demographics**

	Proximal	Distal
	(n=17)	(n=57)
Prior PCI	5 (29%)	14 (25%)
Clinical diagnosis		
Stable angina	5 (29%)	18 (31%)
Unstable angina	9 (53%)	34 (60%)
Acute MI	3 (18%)	5 (9%)

## **Lesion Characteristics**

	Proximal	Distal
	(n=17)	(n=57)
In-stent restenosis	1 (7%)	9 (21%)
Diseased vessel		
1 vessel	4 (24%)	20 (35%)
2 vessel	4 (24%)	14 (25%)
3 vessel	5 (29%)	9 (16%)
LMCA only	4 (24%)	14 (25%)

### **Lesion Characteristics**

	Proximal	Distal
	(n=17)	(n=57)
Proximal reference (mm)		$4.0 \pm 0.6$
Distal reference (mm)	$3.6 \pm 0.6$	$2.9 \pm 0.5$ *
Lesion length (mm)	$7.6 \pm 2.7$	$22.4 \pm 14.4$
Minimal lumen diameter (mm)	$1.6 \pm 0.5$	$1.2 \pm 0.5$
Diameter stenosis (%)	$55.9 \pm 9.6$	$63.7 \pm 15.6$

\* Reference vessel size of LAD

# **Used Cypher Stents**

	Proximal	Distal
	(n=17)	(n=57)
Used No. of stents	17	89
Single stent	17 (100%)	32 (56%)
Two stents	0	19 (33%)
$\geq$ Three stents	0	6 (11%)
Used stent size		
2.5 mm	0	3 (3%)
2.75 mm	0	6 (7%)
3.0 mm	6 (35%)	35 (39%)
3.5 mm	11 (65%)	45 (51%)

# **Stenting Procedure**

	Proximal	Distal
	(n=17)	(n=57)
Use of Abciximab	1 (6%)	4 (7%)
Debulking atherectomy	0	2 (4%)
IVUS guidance	14 (82%)	53 (93%)
Direct stenting	9 (53%)	24 (42%)
Use of a additional high pressure balloon	13 (77%)	30 (54%)
Maximal inflation pressure (atm)	$18.7 \pm 2.4$	$18.5 \pm 3.7$
Maximal balloon diameter (mm)	$3.8\pm0.3$	$4.1 \pm 2.8$
Balloon-to-artery ratio	$1.1 \pm 0.1$	$1.1 \pm 0.1$

#### **Different Stenting Technique** for Distal LMCA Narrowing

#### Final kissing balloon inflation : 30 pts (53%)



#### **Minimal Lumen Diameter**



#### **Diameter Stenosis**

#### Proximal LMCA Distal LMCA



#### Immediate Outcomes in 30 days

#### **Procedural success 100%**

Death0Q MI0Non Q MI \*4 (5 %)Emergent CABG0Repeat PCI0

\* All procedure related, CK-MB  $\geq$  3 times normal value

#### Angiographic Follow-Up at 6 Months

# Performed in 4 patients without restenosis

# **IVUS Analysis**

	Baseline	Postprocedure
Vulnerable plaque	34 %	
Proximal reference		
EEM CSA	$19.9 \pm 5.3$	$22.4\pm0.2$
Lumen CSA	$11.1 \pm 2.9$	$12.2 \pm 0.6$
Target segment		
EEM CSA	$18.5 \pm 5.3$	$19.7\pm6.0$
Lumen CSA	$3.0 \pm 0.7$	$9.3 \pm 2.3$
Distal reference segment		
EEM CSA	$17.1 \pm 5.0$	$16.9 \pm 5.4$
Lumen CSA	$10.1 \pm 3.3$	$10.4\pm4.3$
Stent inapposition		18 %

EEM=external elastic membrane, CSA=cross sectional area

Cardiovascular Research Foundation

#### Conclusions

- Sirolimus eluting stent implantation for unprotected LMCA stenosis was safe with favorable early outcome.
- Long-term angiographic and clinical results will be presented in next year.